Acurx Pharmaceuticals, Inc. (ACXP) Enrolls First Patient in PATHFINDER rCDI Trial

Acurx enrolled the first patient in PATHFINDER, a fully funded ~20-patient Phase 2 open-label rCDI study of ibezapolstat intended to support a potential NDA based on a single Phase 3 trial. A larger non-inferiority Phase 3 (ASPIRE) is planned subject to funding.Material DetailsContext by AI Analyst…